Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.02 |
---|---|
High | 4.99 |
Low | 3.70 |
Bid | 4.29 |
Offer | 4.31 |
Previous close | 26.48 |
Average volume | 3.05m |
---|---|
Shares outstanding | 47.98m |
Free float | 41.56m |
P/E (TTM) | -- |
Market cap | 1.27bn USD |
EPS (TTM) | -0.3772 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
- Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
- Cassava Sciences to Hold Corporate Update on November 25th
- Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
- Cassava Sciences Reports Q3 2024 Financial and Operating Results
- Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
- Cassava Sciences Resolves SEC Investigation
- Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
- Cassava Sciences Names Rick Barry as Chief Executive Officer
- Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
- Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
More ▼